All News

RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021. “SpA” talk by Prof. Désirée van der Heijde. Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏 /TK https://t.co/JFr3VC8sXY
ARD & RMD Open ARD_BMJ ( View Tweet)
Novel MOA Rx SLE skin #OP0132 Iberdomide: high affinity cereblon ligand ➡️proteasomal degradation of Ikaros&Aiolos - works for SCLE & CCLE - works early 4 wks, cont improves at 24 wks - high PCB resp wk 24, CLASI nonsig - dose dept AE's ⬇️WBC, infx, rash #EULAR2021 @rheumnow https://t.co/wYLdAZLvJq
k dao KDAO2011 ( View Tweet)

What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

Paul Studenic Stiddyo ( View Tweet)
“When patients present with LN, they already lost alot of nephrons!” - Prof F Houussiau on the importance of early aggressive Rx for LN #EULAR2021 @rheumnow

k dao KDAO2011 ( View Tweet)

Patient with SLE says I am flaring BUT you say No! Just like in RA, there often is poor QoL. POS0101 Despite response to Rx SF36 shows less QoL vs pop’n. Need to look at what can be improved beyond active SLE #EULAR ⁦@RheumNow⁩ ⁦@eular_org⁩ https://t.co/C17FRTBsUq
Janet Pope Janetbirdope ( View Tweet)
RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg
Janet Pope Janetbirdope ( View Tweet)
OPO132: Dr. Werth presents Iberdomide targeting cereblon ligand on SLE skin. Iberdomide 0.45 mg QD showed improvement vs PBO for SCLE & CCLE, not seen for ACLE. Interesting new target, affects B cell and type 1 IFN pathways @Rheumnow #Eular2021 https://t.co/nuDM7h59MB
Eric Dein ejdein1 ( View Tweet)
Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24. #psoriaticarthritis https://t.co/S3xnFSQDaJ

Links:

Rheumatology Network RheumatologyNet ( View Tweet)

PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2021 OP0133 retinal toxicity with HCQ use. ⬆️ risk: ⭐️Duration 10-14.9 yr (OR 5) ⭐️Duration >15 yr (OR 19) ⭐️Dose >7 mg/kg/d (OR 4.6) ⭐️Cum dose >2000 g Atherosclerosis, age >80 seen in multi-var analysis But didn't have HCQ levels to predict risk @MaxKonigMD @RheumNow https://t.co/DzWWm0U64L
Eric Dein ejdein1 ( View Tweet)
TNFi use associated with ⬇️ radiographic sacroilitis progression in patients with AxSpA ⭐️effect becomes evident between 2 and 4 years after treatment Abs#OP0137 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Machine learning to model risk for SSc-ILD ⭐️predict time to lung function decline ⭐️needs larger sample size Abs#OP0150 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

OP0186 #EULAR2021 by Dr. Mariele Gatto. Anti-cancer effect of immunotherapy with ICI is believed to be mediated by CD8 positive Tc cells. It is not known if other cells get activated. This study looks at B cells. Transitional B cells ⬆️ in ICI induced arthritis (CP-IA). /TK https://t.co/szFF81SKVL
ARD & RMD Open ARD_BMJ ( View Tweet)
No requirement to stop cDMARDs before surgery. For biologics stop 1 dose before and restart 14 days post op, JAKi stop 7 days before, restart 14 days post op, glucocorticoids >10mg/day increases risk of infection in #rheumatoidarthritis Michael D George #EULAR2021

Dr. Antoni Chan synovialjoints ( View Tweet)

#POS0093 Collaborative registry studies are to be encouraged! BUT @k_lauper outlines the heterogenity between registries concerning #AE reporting - Jak-pot study - 18 registries with #RA patients on #tofacitinib - Rates of discontinuation vary across registry #EULAR2021 @RheumNow https://t.co/oczJAG8hzv
Paul Studenic Stiddyo ( View Tweet)
SPACING trial OP0138 at #EULAR2021 ⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo) ⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx ⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Immune events with #checkpointinhibitors 🧐which are the most common? Interesting talk by Maria Suarez-Almazor at #EULAR2021 @eular_org https://t.co/PFPPL4cqOG
EMEUNET EMEUNET ( View Tweet)
You put a pt on a #Jaki What is most likely infection that will occur? #EULAR2021 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

So how do irAEs work? Dr. Anne Bass @lovetolearn27 @HSpecialSurgery gives #EULAR2021 a possible conceptual framework @LCalabreseDO @CCalabreseDO @cappelliMD @got_rheum @MarieKostine and so many other good people! @RheumNow https://t.co/5eOZDwkGO6
David Liew drdavidliew ( View Tweet)
×